高Decipher基因组风险评分与前列腺癌主动监测中主要病理进展相关
本研究纳入486例接受主动监测且至少两次活检并完成Decipher检测的前列腺癌患者,评估Decipher评分与后续活检病理升级的关联。多变量Cox回归显示,高Decipher风险与主要升级(GG≥3)及不良组织学独立相关,但与任何升级无关。低Decipher风险患者或可考虑降低监测强度。
要点
- Decipher高风险(评分≥0.6)与主要升级独立相关(HR 2.00-2.65)。
- Decipher评分与不良组织学相关,但调整CAPRA后高风险的关联不显著。
- Decipher评分与任何升级无显著关联。
核心结论
- 高Decipher基因组风险评分与主动监测患者的主要病理升级和不良组织学相关,低风险患者或可降低监测强度。
研究设计与样本
- 回顾性队列研究,纳入486例接受主动监测、至少两次活检且完成Decipher检测的前列腺癌患者。
主要发现
- Decipher评分与主要升级相关(调整CAPRA后HR 3.37,95%CI 1.17-9.69)。
- 高Decipher风险与主要升级相关(调整CAPRA后HR 2.00,95%CI 1.14-3.49;调整临床人口学变量后HR 2.65,95%CI 1.36-5.17)。
- Decipher评分与不良组织学相关(调整CAPRA后HR 3.68,95%CI 1.03-13.08)。
- 高Decipher风险与不良组织学相关(调整临床人口学变量后HR 4.53,95%CI 2.03-10.15),但调整CAPRA后不显著。
- Decipher评分与任何升级无显著关联。
关键数值与推荐
- Decipher高风险定义为评分≥0.6。
- 诊断活检时,78%为低风险、22%为中风险(按CAPRA评分),12%为高风险(按Decipher)。
临床怎么用
- 对主动监测患者可考虑Decipher检测以识别主要病理升级高风险者。
- 低Decipher风险患者或可考虑降低监测强度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genomic testing has potential to improve clinical decision-making for men with prostate cancer, but is understudied for active surveillance (AS), the standard management option for favorable-risk disease. We investigated whether Decipher scores are associated with AS outcomes in a cohort of patients on AS with at least two biopsies and a Decipher test. Decipher high-risk was defined as a score ≥0.6. Primary outcomes were any upgrading (any increase in grade group [GG]), major upgrading (GG ≥3), and unfavorable histology on subsequent biopsy. Multivariable Cox proportional-hazards regression models were generated for the cohort of 486 patients. On diagnostic biopsy, 78% had low risk and 22% had intermediate risk according to Cancer of the Prostate Risk Assessment (CAPRA) scores, and 12% had high risk according to Decipher. Decipher scores were associated with major upgrading after adjusting for CAPRA scores (hazard ratio [HR] 3.37, 95% confidence interval [CI] 1.17-9.69); high Decipher risk was associated with major upgrading after adjustment for either the CAPRA score (HR 2.00, 95% CI 1.14-3.49) or clinicodemographic variables (HR 2.65, 95% CI 1.36-5.17). The Decipher score was associated with unfavorable histology after adjustment for the CAPRA score (HR 3.68, 95% CI 1.03-13.08); high Decipher risk was associated with unfavorable histology after adjustment for clinicodemographic variables (HR 4.53, 95% CI 2.03-10.15) but not after adjustment for the CAPRA score. No association was observed for any upgrading. Deintensification of surveillance may be warranted for patients with lower Decipher risk.
引用
- Shee K, Pace WA, Song JJ, et al. A High Decipher Genomic Risk Score Is Associated with Major Pathological Progression in Patients Undergoing Active Surveillance for Prostate Cancer. Eur Urol Oncol. 2026. PMID: 41620335. doi:10.1016/j.euo.2026.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。